66 results on '"Čermák, J."'
Search Results
2. P095 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE
3. P063 - Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: HEMATOPOIETIC STEM CELLS OF LOWER-RISK MDS PATIENTS WITH RAPID PROGRESSION SHOW QUIESCENT-LIKE CELL STATE SIMILAR TO THAT OF HIGHER-RISK MDS CELLS
4. P24 - Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: MUTATIONS IN RUNX1 GENE CONTRIBUTE TO THE PROGRESSION OF LOWER-RISK MDS PATIENTS BY DISRUPTING CELLULAR PROTECTION AGAINST MALIGNANT TRANSFORMATION
5. P25 - Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: NONCODING RNAS IN MDS PATHOGENESIS AND THEIR PREDICTIVE VALUE IN AZACITIDINE RESPONSE
6. P22 - Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: THE DEL(5Q) SIZE IN MDS IS CORRELATED TO KARYOTYPE COMPLEXITY AND FREQUENCY OF TP53 MUTATIONS
7. P08 - Topic: AS02-Epidemiology: TEN YEARS OF THE CZECH MDS REGISTRY: REAL LIFE DATA AND EXPERIENCES
8. O08 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: LYMPHOPENIA IS HIGHLY PREVALENT IN MDS AND PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR IPSS-R VERY-LOW AND LOW-RISK PATIENTS. AN ANALYSIS FROM THE EU-MDS REGISTRY
9. P075 Characteristics of patients with therapy-related myelodysplastic syndrome
10. P081 The questions on megakaryopoiesis in MDS patients with del(5q)
11. P047 Determining of intensity methylation in the area of promoter gene P15INK4B as prognostic marker in patients with myelodysplastic syndromes (MDS)
12. P028 Survival, prognostic factors, and leukemic transformation in a multicenter study of 241 patients with MDS and del(5q)
13. P026 A limited benefit of isolated 5q deletion on prognosis – results of a long term retrospective analysis
14. P015 European LeukemiaNet registry programme for low/INT-1 IPSS score myelodysplastic syndromes
15. C011 Gene methylation, telomere length and activity of telomerase reflect the disease activity in MDS patients and may help to assess an individual risk of patients
16. C010 Differentially expressed genes of CD34+ between patients with early and advanced myelodysplastic syndrome
17. Prognostic Value of Early Drop in Platelets in Lower-Risk MDS. A Sub-Study from the European Leukemianet Lower-Risk MDS (EUMDS) Registry
18. 280 - Impact of Red Blood Cell Transfusions on Survival in Lower-Risk MDS Patients Included in the European Leukemianet MDS (EUMDS) Registry
19. 241 - Plasma Levels of MIR-451A, MIR-223-3P, and MIR-27A-3P are Predictive of Prognosis in Myelodysplastic Syndromes
20. 237 - Prediction of Disease Progression Using Mutational Screening in Patients with Myelodysplastic Syndrome
21. 228 - MDS Patients with Del(5Q) and Trisomy 8 in Two Independent Clones Have High fli-1 and Cereblon Messenger RNA Levels
22. 227 - High Level of Full-Length Cereblon Messenger RNA and Protein is Important for Lenalidomide Efficacy in Lower Risk MDS Patients
23. 180 - Is the Diagnosis of Patients with Del(5Q) and Trisomy 8 Different, when Found in Unrelated Clones or in One Clone?
24. 90 - Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5Q)
25. 67 - Comparison of Efficiency of Hypomethylating Agents with Allogeneic SCT in Elderly Patients with Advanced MDS – A Single Center Study
26. 57 - Differential Expression of the Homologous Recombination DNA Repair Genes in Early and Advanced Stages of Myelodysplastic Syndrome
27. 22 - Health-Related Quality of Life is Substantially Impaired in Lower-Risk MDS when Compared with Reference Populations and Significantly Affects Overall Survival
28. 19 - Prognostic Value of Early Drop in Platelets in Lower-Risk MDS. A Sub-Study from the European Leukemianet Lower-Risk MDS (EUMDS) Registry
29. 212 TRANSFUSIONS AND PRESENCE OF RINGSIDEROBLASTS INFLUENCE HEPCIDIN AND NTBI LEVELS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) - A REPORT FROM THE EUROPEAN LEUKEMIANET MDS REGISTRY
30. 167 ALTERED EXPRESSION OF THE REPAIR GENES IN CD34+ CELLS MAY BE RESPONSIBLE FOR FORMATION AND ACCUMULATION OF MUTATIONS IN MDS PATIENTS
31. 170 MECHANISM OF FORMATION OF COMPLEX CHROMOSOMAL ABERRATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS): CLONAL EVOLUTION OR CHROMOTHRIPSIS?
32. 103 AZACITIDINE TREATMENT OF HIGH RISK MDS AND AML, ANALYSIS OF LONG RESPONDING PATIENTS AND PROGNOSTIC FACTORS OF OVERALL SURVIVAL, CZECH MDS GROUP EXPERIENCE
33. 106 PATIENTS WITH TWO UNRELATED CLONES DEL(5Q) AND TRISOMY 8 – A SUBTYPE OF 5Q- SYNDOME? UNCERTAIN PROGNOSIS OF PATIENTS WITH DECREASED DEL(5Q) CLONE DUE TO LENALIDOMIDE
34. 51 PROGNOSTIC IMPACT OF TRANSFUSION INTENSITY ON SURVIVAL AND THROMBOCYTOPENIA IN NEWLY DIAGNOSED LOWER-RISK MDS PATIENTS PARTICIPATING IN THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY
35. 49 THE PROGNOSTIC SIGNIFICANCE OF TP53 MUTATIONS IN MDS PATIENTS WITH DEL(5Q)
36. 42 THE EFFICACY OF LENALIDOMIDE IN LOWER RISK MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION IS DEPENDENT ON HIGH LEVEL OF FULL-LENGTH CEREBLON MESSENGER RNA
37. P-220 A comparison of effect of stem cell transplantation (SCT) with different treatment approaches on long term survival of MDS patients
38. P-207 Changes in plasma proteome of myelodysplastic syndrome patients with refractory anemia with excess blasts subtype 2
39. P-203 Plasma proteome changes associated with refractory anemia in patients with myelodysplastic syndrome
40. P-113 Revised International Prognostic Scoring System (IPSS-R) for primary treated myelodysplastic syndromes (MDS) patients: A report from the IWG-PM
41. P-015 Microarray-based miRNA expression profiling in patients with myelodysplastic syndrome with deletion of chromosome 5q treated with lenalidomide
42. P-011 TP53 mutations in low-risk MDS patients with isolated del(5q)
43. O-027 European distribution of usage and impact on outcome for treatment with erythropoietic stimulating agents within the EUMDS lower-risk registry programme
44. 362 Chronic lymphocytic leukemia and myelodysplastic syndrome in a patient with intestinal carcinoma – a case report
45. 301 Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q- MDS (IPSS low and Intermediate-1)
46. 274 The response of FLi1, EKLF, TP53 (p53), PU.1, MDM2 gene expression in 5q- syndrome to lenalidomide treatment
47. 264 Genomic imbalances in 73 patients with MDS and complex karyotypes
48. 250 Are Fli1, EKLF, PU.1, HDM2 and TP53 factors implicated in refractory anemia and megakaryopoiesis in 5q- syndrome?
49. 247 miRNA expression profiling in 5q- syndrome patients treated with lenalidomide
50. 228 Lenalidomide treatment of patients with 5q- syndrome affects genes located in the TNF pathway
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.